Viewpoint March 11, 2015 What will change the NOAC landscape? Inside Edge Consulting, Princeton anticoagulation, apixaban, Consultant group, dabigatran, edoxaban, Health outcomes, Healthcare, Healthcare consultants, NOAC, Payers, Pharmacy, protola, reversal agent, rivaroxaban
Viewpoint March 5, 2015 Impact of edoxaban label Inside Edge Consulting, Princeton atrial fibrillation, edoxaban, FDA, Healthcare, Marketing consultants, novel agents, Payers, Targeted therapy
